Effects of low-dose Dexmedetomidine on gastrointestinal reactions after minimally invasive surgery for cervical cancer
10.3969/j.issn.1007-1989.2017.07.016
- VernacularTitle:小剂量右美托咪定对宫颈癌微创术后胃肠道反应的影响
- Author:
Cailing ZHANG
;
Ting LIAO
;
Yingjia LUO
;
Siyuan FAN
- Keywords:
Dexmedetomidine;
cervical cancer;
gastrointestinal reactions
- From:
China Journal of Endoscopy
2017;23(7):76-79
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of low dose Dexmedetomidine on gastrointestinal reaction after minimally invasive surgery for cervical cancer. Methods 94 patients with cervical cancer treated with minimally invasive surgery from February 2014 to September 2016 were selected. According to the random number table method, the patients were divided into observation group (low-dose Dexmedetomidine) and control group (saline). The incidence of nausea and vomiting, the motilin level were compared between the two groups. Results The observation group was 47 cases, grade Ⅱ nausea in 7 cases, grade Ⅲ nausea in 2 cases, the total incidence was 19.15%; 47 cases in the control group, 11 cases of grade Ⅱ nausea, grade Ⅳ nausea in 4 cases, grade 2 nausea in 2 cases, the rate was 36.17%, the difference was statistically significant (P < 0.05). 47 cases of grade Ⅱ vomiting in 4 cases, grade Ⅲ vomiting in 5 cases, grade Ⅳ vomiting in 1 case, the total incidence rate was 14.89%, grade Ⅱin 4 case, grade Ⅲ vomiting in 5 cases, grade Ⅳ vomiting in 1 case, the total incidence was 21.28%, the difference was statistically significant (P < 0.05). There was no significant difference in motilin level between the two groups (P > 0.05). At 6 h, 12 h and 24 h after operation, the levels of motilin in the observation group were significantly lower than those in the control group, the difference was statistically significant (P < 0.05). Conclusion Low dose Dexmedetomidine can effectively prevent and alleviate the gastrointestinal reaction after minimally invasive surgery for cervical cancer, and avoid the excessive release of motilin, worthy of clinical promoting.
